Bearberry

PreclinicalSmall molecule

UUniversity of Pecs

Bearberry is one of 19 small molecule programs targeting Cystitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystitisActive, not recruiting

CystitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Cystitis

#DrugCompanyPhaseTrials

Ivadantin

PProcter and Gamble

Approved

5 2

Monurol

MMeitheal

Approved

4 3

Advil

KKenvue Brands

Approved

1 4

Oxytrol

WWim Janssens

Approved

1 5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—6

Avycaz

PPhiladelphia Eye Associates

Elmiron

1 8

Raphamin

MMateria Medica Holding

Phase 3

1 9

Gynoflor

MMahidol University

Phase 3

1 10

Sodium Hyaluronate

Sanofi

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystitis1 trial

Bearberry in the Treatment of Cystitis

Unknown status·UUniversity of Pecs·N/A·NCT05055544·504 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bearberry. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bearberry compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bearberry. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pecs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Pecs

Bearberry

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystitis1 trial

References

Drug Info

Quick Facts

Related News